Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates
- PMID: 16006134
- DOI: 10.1016/j.nbd.2005.05.028
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates
Abstract
Changes in the expression of alpha-synuclein are likely to underlie its normal function as well as its role in pathological processes. The relationship between toxic injury and alpha-synuclein expression was assessed in the substantia nigra of squirrel monkeys treated with a single injection of MPTP and sacrificed 1 week or 1 month later. At 1 week, when stereological cell counting revealed only a small decrease (-10%) in the number of dopaminergic neurons, alpha-synuclein mRNA and protein were markedly enhanced. Increased alpha-synuclein immunoreactivity was evident at the level of neuronal fibers whereas nigral cell bodies were devoid of detectable protein. At 1 month post-MPTP, neuronal loss rose to 40%. Both alpha-synuclein mRNA and protein remained elevated but, noticeably, a robust alpha-synuclein immunoreactivity characterized a significant number of cell bodies. Neuromelanin granules are hallmarks of dopaminergic neurons in primates. Therefore, the number of alpha-synuclein-positive cells that also contained neuromelanin was counted throughout the substantia nigra. At 1 month, the vast majority of alpha-synuclein-immunoreactive neurons contained neuromelanin, and approximately 80% of the dopaminergic cell bodies that survived MPTP toxicity stained positive for alpha-synuclein. The results indicate that a single toxic insult is capable of inducing a sustained alpha-synuclein up-regulation in the primate brain. They support a direct relationship between neuronal injury and enhanced alpha-synuclein expression, and suggest that protein elevation within cell bodies may be a late feature of neurons that have endured a toxic stress.
Similar articles
-
Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.Neurochem Int. 2008 Sep;53(3-4):56-62. doi: 10.1016/j.neuint.2008.06.007. Epub 2008 Jun 28. Neurochem Int. 2008. PMID: 18639597
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies.Neurosci Lett. 2005 May 20-27;380(1-2):161-5. doi: 10.1016/j.neulet.2005.01.056. Epub 2005 Feb 3. Neurosci Lett. 2005. PMID: 15854770
-
Glial reactions in Parkinson's disease.Mov Disord. 2008 Mar 15;23(4):474-83. doi: 10.1002/mds.21751. Mov Disord. 2008. PMID: 18044695 Review.
-
Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.Parkinsonism Relat Disord. 2008;14 Suppl 2:S185-8. doi: 10.1016/j.parkreldis.2008.04.028. Epub 2008 Jun 27. Parkinsonism Relat Disord. 2008. PMID: 18585086 Review.
Cited by
-
Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease.PLoS One. 2013 Oct 18;8(10):e78220. doi: 10.1371/journal.pone.0078220. eCollection 2013. PLoS One. 2013. PMID: 24205164 Free PMC article.
-
Loss of RAB39B does not alter MPTP-induced Parkinson's disease-like phenotypes in mice.Front Aging Neurosci. 2023 Jan 25;15:1087823. doi: 10.3389/fnagi.2023.1087823. eCollection 2023. Front Aging Neurosci. 2023. PMID: 36761179 Free PMC article.
-
α-Synuclein in Parkinson's disease: causal or bystander?J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25. J Neural Transm (Vienna). 2019. PMID: 31240402 Review.
-
Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment.ASN Neuro. 2018 Jan-Dec;10:1759091418777438. doi: 10.1177/1759091418777438. ASN Neuro. 2018. PMID: 29809058 Free PMC article.
-
A critical evaluation of the Braak staging scheme for Parkinson's disease.Ann Neurol. 2008 Nov;64(5):485-91. doi: 10.1002/ana.21541. Ann Neurol. 2008. PMID: 19067353 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources